|
195 Companies |
|
327 Products |
|
327 Products |
|
167 Mechanisms of Action |
|
13 Trials |
|
3266 News |
|
| «12...2526272829303132333435...6768» |
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment status, Trial primary completion date: Evaluation Of Acceptability And Satisfaction Of Hemophilia Patients Treated With FusENGO (clinicaltrials.gov) - Feb 2, 2015
P4, N=200, Recruiting, Sponsor: Pfizer
Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2015 --> Jan 2016
- bortezomib / Generic mfg., lenalidomide / Generic mfg.
New P2 trial, Post-transplantation: Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 2, 2015
P2, N=3, Terminated, Sponsor: University of Colorado, Denver
- bortezomib / Generic mfg., melphalan / Generic mfg.
New P1/2 trial: Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma (clinicaltrials.gov) - Feb 2, 2015
P1/2, N=2, Terminated, Sponsor: University of Colorado, Denver
- busulfan / Generic mfg.
Enrollment closed, Trial primary completion date: Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant (clinicaltrials.gov) - Feb 2, 2015
P0, N=30, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Enrolling by invitation --> Recruiting | Trial primary completion date: Aug 2015 --> Jan 2016 Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015
- Enrollment closed, Enrollment change: Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies (clinicaltrials.gov) - Feb 2, 2015
P1, N=9, Active, not recruiting, Sponsor: Robert Lowsky
Recruiting --> Active, not recruiting | Trial primary completion date: Dec 2014 --> Jul 2015 Recruiting --> Active, not recruiting | N=18 --> 9
- || linsitinib (ASP7487) / Sling Therap
Trial primary completion date, Combination therapy: A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma (clinicaltrials.gov) - Jan 30, 2015
P1/2, N=75, Recruiting, Sponsor: University Health Network, Toronto
Recruiting --> Active, not recruiting | N=18 --> 9 Trial primary completion date: Dec 2015 --> Jun 2016
- melphalan / Generic mfg., lenalidomide / Generic mfg.
Trial primary completion date: Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis (clinicaltrials.gov) - Jan 30, 2015
P2, N=35, Active, not recruiting, Sponsor: Boston Medical Center
Trial primary completion date: Dec 2015 --> Jun 2016 Trial primary completion date: Jul 2014 --> Jul 2016
- || dexamethasone / Generic mfg.
New P3 trial: Caffeic Acid Tablets as a Second-line Therapy for ITP (clinicaltrials.gov) - Jan 30, 2015
P3, N=200, Recruiting, Sponsor: Shandong University
- | Rituxan (rituximab) / Biogen, Zenyaku Holdings, Roche
Enrollment change: Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma (clinicaltrials.gov) - Jan 28, 2015
P2, N=21, Active, not recruiting, Sponsor: Mayo Clinic
Trial primary completion date: Jul 2014 --> Jul 2016 N=36 --> 21
- Trial primary completion date: UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2015
P2, N=20, Recruiting, Sponsor: University of Arkansas
N=36 --> 21 Trial primary completion date: Jan 2015 --> Jan 2016
- Neupogen (filgrastim) / Kyowa Kirin, Amgen
Clinical: Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 26, 2015
P0, N=7, Terminated, Sponsor: Washington University School of Medicine
Trial primary completion date: Jan 2015 --> Jan 2016 Active, not recruiting --> Terminated; Unexpected toxicity (2 early deaths)
- Mekinist (trametinib) / Novartis, BeiGene
Trial initiation date, Trial primary completion date: UARK 2014-08 A Phase II Open-Label, Multiple-Dose, Single Agent Study to Evaluate the Overall Response Rate of Orally Administered Trametinib (clinicaltrials.gov) - Jan 26, 2015
P2, N=23, Not yet recruiting, Sponsor: University of Arkansas
Active, not recruiting --> Terminated; Unexpected toxicity (2 early deaths) Initiation date: Aug 2014 --> Aug 2015 | Trial primary completion date: Jun 2015 --> Jun 2016
- ||||||| thalidomide / Generic mfg.
Trial completion, Post-transplantation: UARK 98-026 TT II: Multiple Myeloma Evaluating Anti-Angiogenesis With Thalidomide and Post-Transplant Consolidation Chemotherapy (clinicaltrials.gov) - Jan 26, 2015
P3, N=673, Completed, Sponsor: University of Arkansas
Initiation date: Aug 2014 --> Aug 2015 | Trial primary completion date: Jun 2015 --> Jun 2016 Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2014 | Active, not recruiting --> Completed
- ||||||| Nuwiq (simoctocog alfa) / Octapharma
Trial completion: NuPreviq: Assess the Safety and Efficacy of Individually Tailored Prophylaxis With Human-cl rhFVIII in Patients With Severe Haemophilia A (clinicaltrials.gov) - Jan 22, 2015
P3, N=66, Completed, Sponsor: Octapharma
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Aug 2014 | Active, not recruiting --> Completed Active, not recruiting --> Completed
- warfarin / Generic mfg.
Biomarker, Trial completion, Trial primary completion date: Pharmacogenetics of Warfarin in Puerto Ricans. (clinicaltrials.gov) - Jan 22, 2015
P=N/A, N=350, Completed, Sponsor: University of Puerto Rico
Active, not recruiting --> Completed Recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jul 2014
- | Promacta (eltrombopag) / Novartis
Trial completion: Drug-drug Interaction Study of Eltrombopag and Cyclosporine in Healthy Subjects (clinicaltrials.gov) - Jan 20, 2015
P1, N=39, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed | Trial primary completion date: Apr 2014 --> Jul 2014 Not yet recruiting --> Completed
- ||| Kogenate FS (octocog alfa sucrose formulation) / CSL Behring, Bayer
Trial completion: Effekt-2 - Efficacy and Safety of Long-term Treatment With KOGENATE (clinicaltrials.gov) - Jan 20, 2015
P=N/A, N=105, Completed, Sponsor: Bayer
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| Clinical data, Enrollment open, HEOR: HAMLET: 2-cohort Study of Adult Patients With Severe Hemophilia A in Greece (clinicaltrials.gov) - Jan 18, 2015
P=N/A, N=75, Recruiting, Sponsor: Bayer
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Trial primary completion date: Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM (clinicaltrials.gov) - Jan 17, 2015
P2, N=30, Recruiting, Sponsor: Azienda Ospedaliera di Bolzano
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2013 --> Aug 2015
- || Xyntha (moroctocog alfa) / Pfizer
Enrollment status, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Jan 15, 2015
P4, N=140, Recruiting, Sponsor: Pfizer
Trial primary completion date: Jun 2013 --> Aug 2015 Enrolling by invitation --> Recruiting
- Trial primary completion date: Safety Study of Spray-Dried Solvent/Detergent-Treated Plasma for Infusion in Healthy Volunteers (clinicaltrials.gov) - Jan 15, 2015
P1, N=26, Recruiting, Sponsor: Entegrion, Inc.
Enrolling by invitation --> Recruiting Trial primary completion date: Jun 2014 --> Jun 2015
- | busulfan / Generic mfg., clofarabine / Generic mfg.
Trial completion: Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen (clinicaltrials.gov) - Jan 13, 2015
P1/2, N=46, Completed, Sponsor: University of Michigan Cancer Center
Trial primary completion date: Jun 2014 --> Jun 2015 Active, not recruiting --> Completed
- Proleukin (aldesleukin) / Merck (MSD), Novartis, Iovance Biotherap
Trial primary completion date: Interleukin-2 Treatment for Wiskott-Aldrich Syndrome (clinicaltrials.gov) - Jan 13, 2015
P1, N=9, Recruiting, Sponsor: Soma Jyonouchi
Active, not recruiting --> Completed Trial primary completion date: Oct 2015 --> Oct 2016
- BeneFix (nonacog alfa) / Pfizer
Trial initiation date: An Open-Label, Single Dose Pharmacokinetic Study of Benefix (Recombinant Factor IX) in Male Chinese Subjects With Hemophilia B (clinicaltrials.gov) - Jan 13, 2015
P1, N=12, Not yet recruiting, Sponsor: Pfizer
Trial primary completion date: Oct 2015 --> Oct 2016 Initiation date: Oct 2014 --> Jan 2015
- Trial primary completion date: Geriatric Assessments in Senior Adults With Multiple Myeloma (clinicaltrials.gov) - Jan 12, 2015
P=N/A, N=42, Active, not recruiting, Sponsor: Washington University School of Medicine
Initiation date: Oct 2014 --> Jan 2015 Trial primary completion date: May 2015 --> Dec 2014
- ||||| BeneFix (nonacog alfa) / Pfizer
New P4 trial: Safety and Efficacy of Benefix in Patients With Hemophilia B in Usual Care Settings in China (clinicaltrials.gov) - Jan 12, 2015
P4, N=68, Not yet recruiting, Sponsor: Pfizer
- ||||||| Abstilla (lonoctocog alfa) / CSL Behring, Kovaltry (octocog alfa) / Bayer, CSL Behring
Trial completion, Enrollment change: An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A (clinicaltrials.gov) - Jan 12, 2015
P2/3, N=175, Completed, Sponsor: CSL Behring
Trial primary completion date: May 2015 --> Dec 2014 Active, not recruiting --> Completed | N=104 --> 175
- Reolysin (pelareorep) / Oncolytics, Andrus Reo
Trial primary completion date: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 12, 2015
P1, N=12, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed | N=104 --> 175 Trial primary completion date: Dec 2014 --> Mar 2015
- Enrollment change, Trial primary completion date: Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant (clinicaltrials.gov) - Jan 12, 2015
P2, N=2, Terminated, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2014 --> Mar 2015 N=45 --> 2 | Trial primary completion date: Jul 2025 --> Feb 2014
- || ontuxizumab (MORAb-004) / Eisai
Enrollment closed: MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma (clinicaltrials.gov) - Jan 12, 2015
P1, N=65, Active, not recruiting, Sponsor: Morphotek
N=45 --> 2 | Trial primary completion date: Jul 2025 --> Feb 2014 Recruiting --> Active, not recruiting
- Trial completion, Enrollment change: PUCHS: Project to Update the Study of Congenital Haemophilia in Spain (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=1157, Completed, Sponsor: Novo Nordisk A/S
Recruiting --> Active, not recruiting Enrolling by invitation --> Completed | N=2500 --> 1157
- Trial completion: ECCTEG: Platelet Function in Minimal Extracorporeal Circulation in CABG (clinicaltrials.gov) - Jan 9, 2015
P=N/A, N=40, Completed, Sponsor: Catharina Ziekenhuis Eindhoven
Enrolling by invitation --> Completed | N=2500 --> 1157 Recruiting --> Completed
- | bendamustine / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: Study of SyB L-0501 to Treat Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Jan 9, 2015
P2, N=17, Completed, Sponsor: SymBio Pharmaceuticals
Recruiting --> Completed Recruiting --> Completed | N=44 --> 17 | Trial primary completion date: Dec 2014 --> Jul 2013
- || cyclophosphamide / Generic mfg., pomalidomide / Generic mfg.
Combination therapy: Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide (clinicaltrials.gov) - Jan 8, 2015
P1/2, N=80, Active, not recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
Recruiting --> Completed | N=44 --> 17 | Trial primary completion date: Dec 2014 --> Jul 2013 Trial primary completion date: Apr 2015 --> Dec 2015
- dexamethasone / Generic mfg., prednisone / Generic mfg.
New P3 trial: EIS2002: Daily Prednisone Versus Pulsed Dexamethasone in Treatment-na (clinicaltrials.gov) - Jan 8, 2015
P3, N=26, Completed, Sponsor: University Hospital, Essen
- Fibryga (fibrinogen concentrate (human)) / Octapharma
Trial primary completion date: Pharmacokinetic, Efficacy, and Safety Study of Octafibrin Compared to Haemocomplettan/Riastap (clinicaltrials.gov) - Jan 7, 2015
P2, N=18, Recruiting, Sponsor: Octapharma
Trial primary completion date: Apr 2015 --> Dec 2015 Trial primary completion date: Jul 2014 --> Jan 2015
- Enrollment closed, Enrollment change: Geriatric Assessments in Senior Adults With Multiple Myeloma (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=42, Active, not recruiting, Sponsor: Washington University School of Medicine
Trial primary completion date: Jul 2014 --> Jan 2015 Recruiting --> Active, not recruiting | N=30 --> 42
- lenalidomide / Generic mfg., thalidomide / Generic mfg., pomalidomide / Generic mfg.
Clinical: Continuous Lenalidomide Therapy Versus Observation Following Induction Without Lenalidomide, Pomalidomide or Thalidomide in Myeloma (clinicaltrials.gov) - Jan 6, 2015
P3, N=0, Withdrawn, Sponsor: Celgene Corporation
Recruiting --> Active, not recruiting | N=30 --> 42 N=172 --> 0 | Terminated --> Withdrawn
- Keytruda (pembrolizumab) / Merck (MSD)
New P2 trial: Phase 2 Multi-center Study of Anti-PD-1 During Lymphopenic State After HDT/ASCT for Multiple Myeloma (clinicaltrials.gov) - Jan 6, 2015
P2, N=50, Not yet recruiting, Sponsor: University of Michigan Cancer Center
- Enrollment change, Trial withdrawal: Non Neutralizing Antibodies: Prevalence and Characterization (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=0, Withdrawn, Sponsor: University Hospital, Montpellier
N=172 --> 0 | Terminated --> Withdrawn N=300 --> 0 | Recruiting --> Withdrawn
- ||| Empliciti (elotuzumab) / AbbVie, BMS, lirilumab (BMS-986015) / Innate, BMS, Ono Pharma, urelumab (BMS-663513) / BMS, Ono Pharma
Enrollment open, Combination therapy: A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma (clinicaltrials.gov) - Jan 2, 2015
P1, N=136, Recruiting, Sponsor: Bristol-Myers Squibb
N=300 --> 0 | Recruiting --> Withdrawn Not yet recruiting --> Recruiting
- deferasirox tablet for oral suspension / Generic mfg.
Trial completion: Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies (clinicaltrials.gov) - Jan 2, 2015
P=N/A, N=16, Completed, Sponsor: Comprehensive Cancer Center of Wake Forest University
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- long-acting sequence-modified recombinant factor VIIa (BAY 866150) / Bayer
Trial termination: A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150 (clinicaltrials.gov) - Dec 30, 2014
P2/3, N=10, Terminated, Sponsor: Bayer
Active, not recruiting --> Completed Completed --> Terminated
- danazol oral / Generic mfg.
Trial primary completion date: Safety Study of Danazol With Plasma Exchange and Steroids for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP) (clinicaltrials.gov) - Dec 30, 2014
P2, N=25, Recruiting, Sponsor: Beth Israel Medical Center
Completed --> Terminated Trial primary completion date: Dec 2014 --> Dec 2015
- | Farydak (panobinostat) / Secura Bio
Phase classification, Combination therapy: MACS1271: Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma (clinicaltrials.gov) - Dec 30, 2014
P2, N=55, Completed, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Dec 2014 --> Dec 2015 Phase classification: P4 --> P2
- Trial completion, Enrollment change, Trial primary completion date, Biopsy: Skin Biopsies in Chemotherapy-Induced Neuropathy (clinicaltrials.gov) - Dec 25, 2014
P=N/A, N=26, Completed, Sponsor: Erasmus Medical Center
Phase classification: P4 --> P2 Recruiting --> Completed | N=100 --> 26 | Trial primary completion date: Nov 2011 --> Feb 2012
- || carfilzomib / Generic mfg.
Clinical: A Study of Extended Carfilzomib Therapy for Patients Previously Enrolled in Carfilzomib Treatment Protocols (clinicaltrials.gov) - Dec 25, 2014
P2, N=100, Active, not recruiting, Sponsor: Onyx Therapeutics, Inc.
Recruiting --> Completed | N=100 --> 26 | Trial primary completion date: Nov 2011 --> Feb 2012 Trial primary completion date: Apr 2014 --> Dec 2015
- || bortezomib / Generic mfg.
Trial primary completion date, HEOR: Quality of Life in Multiple Myeloma Patients Treated With Bortezomib (clinicaltrials.gov) - Dec 24, 2014
P4, N=140, Completed, Sponsor: Janssen Korea, Ltd., Korea
Trial primary completion date: Apr 2014 --> Dec 2015 Trial primary completion date: Feb 2009 --> Jul 2008
- Trial initiation date: Observational Registry of the Treatment of Glanzmann's Thrombasthenia (clinicaltrials.gov) - Dec 24, 2014
P=N/A, N=218, Completed, Sponsor: Novo Nordisk A/S
Trial primary completion date: Feb 2009 --> Jul 2008 Initiation date: May 2007 --> Jan 2004
- ||| Xyntha (moroctocog alfa) / Pfizer
Enrollment status, Phase classification, Enrollment change, Trial initiation date, Adverse events: Study Evaluating Pharmacovigilance Of Refacto AF (clinicaltrials.gov) - Dec 24, 2014
P4, N=140, Enrolling by invitation, Sponsor: Pfizer
Initiation date: May 2007 --> Jan 2004 Recruiting --> Enrolling by invitation | Phase classification: PN/A --> P4 | N=180 --> 140 | Initiation date: Nov 2009 --> Jul 2009